Zobrazeno 1 - 10
of 58
pro vyhledávání: '"Fabio Bonilla Abadía"'
Autor:
Carlos A. Cañas, Fabio Bonilla Abadía
Publikováno v:
Autoimmune Diseases, Vol 2012 (2012)
In the recent years, it has been of great interest to study the binding mechanism between the innate and adaptive immune responses as interrelated processes for the development of multiple autoimmune diseases. Infection has been a well-known trigger
Externí odkaz:
https://doaj.org/article/057b5e3d53514dcab768f6c6d84054b8
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 27 (2021)
COVID-19 (Coronavirus Disease 2019) is a highly contagious infection and associated with high mortality rates, primarily in elderly; patients with heart failure; high blood pressure; diabetes mellitus; and those who are smokers. These conditions are
Externí odkaz:
https://doaj.org/article/78bef9cd6bc34fe2b1987df487ae4223
Autor:
Ingrid Ruiz-Ordóñez, Víctor A Santos, Fabio Bonilla-Abadía, Nhora Silva, Aura Sánchez, Gabriel J Tobón, Carlos A Cañas
Publikováno v:
Modern rheumatology case reports. 7(1)
Rituximab is indicated in some patients with refractory systemic lupus erythematosus (SLE). Occasionally, this medication is required in chronic form to maintain control of the disease. We described two patients who developed lymphoid follicular hype
Publikováno v:
Journal of Thrombosis and Thrombolysis
In December 2019, a new and highly contagious infectious disease emerged in Wuhan, China. The etiologic agent was identified as a novel coronavirus, now known as Severe Acute Syndrome Coronavirus-2 (SARS-CoV-2). Recent research has revealed that viru
Publikováno v:
Revista Colombiana de Reumatología (English Edition). 25:132-135
Salmonella enteritidis infection (SEI) is rare in systemic lupus erythematosus (SLE) patients, and it is often mistaken with SLE flares. SEI in SLE patients has been associated with a poor outcome. A description is presented of the clinical features
Publikováno v:
Revista Colombiana de Reumatología. 25:132-135
Resumen La infeccion por Salmonella enteritidis (ISE) es rara en pacientes con lupus eritematoso sistemico (LES), y comunmente se confunde con exacerbaciones del LES. ISE en pacientes con LES se ha relacionado con malos desenlaces. Este articulo desc
Autor:
Juliana Escobar-Stein, Carlos A. Cañas, Alex Echeverri, Erika-Paola Navarro, Juan-Pablo Suso, Iván Posso-Osorio, Magali Chamorro, Gabriel J. Tobón, Fabio Bonilla-Abadía, Juan Carlos Bravo, Andrés Hormaza
Publikováno v:
Revista Colombiana de Reumatología (English Edition). 25:69-74
IgG4-related disease is an inflammatory systemic condition noted by the infiltration of different organs by IgG4-bearing plasma cells, as well as elevated serum IgG4 levels. Diagnosis of this condition is complex, and clinical findings are not partic
Autor:
Carlos A. Cañas, Erika-Paola Navarro, Alex Echeverri, Fabio Bonilla-Abadía, Juliana Escobar-Stein, Magali Chamorro, Juan-Pablo Suso, Iván Posso-Osorio, Gabriel J. Tobón, Juan-Carlos Bravo, Andrés Hormaza
Publikováno v:
Revista Colombiana de Reumatología. 25:69-74
Resumen La enfermedad relacionada con IgG4 es una condicion inflamatoria sistemica, caracterizada por la infiltracion de diversos organos por complejos formados por celulas plasmaticas IgG4 positivas, asociadas con niveles elevados de IgG4 en el suer
Autor:
Juan-Carlos Bravo, Fabio Bonilla-Abadía, Carlos A. Cañas, Gabriel J. Tobón, David Aguirre-Valencia, Iván Posso-Osorio
Publikováno v:
Clinical Rheumatology. 36:2159-2162
Eosinophilic granulomatosis with polyangiitis (EGPA), formerly known as Churg-Strauss syndrome (CSS), is a small vessel vasculitis associated with eosinophilia and asthma. Clinical manifestations commonly seen in patients presenting with EGPA range f
Autor:
Fabio Bonilla-Abadía, Alex Echeverri, Andrés Agualimpia, Carlos A. Cañas, Iván Posso-Osorio, Juan-Pablo Suso, Christian Figueroa, Andrés Hormaza, Gabriel J. Tobón
Publikováno v:
Revista Colombiana de Reumatología. 24:159-163
Resumen Introduccion El belimumab es un anticuerpo monoclonal tipo IgG1 que se une e inhibe la forma soluble de Blys (estimulador de linfocitos B) y ha mostrado efectividad en el manejo del lupus eritematoso sistemico (LES). Sin embargo, se desconoce